Sign in

Dalila

@dalilatm.bsky.social
276 followers 375 following 251 posts

Interested in research ethics and all about #lupus #lupusnephritis | Running support group #Wales 🏴󠁧󠁢󠁷󠁬󠁳󠁿| We need a cure for Lupus 🦋 #MyViews

PostsRepliesMedia
Reposted by Dalila
University of Oxford @ox.ac.uk · 28/09/2026
Researchers are developing more precise ways to target the neural circuits involved in learning, with potential applications across sport, music, surgery and rehabilitation. As the technology advances, discover what the science tells us about its potential ⬇️ bit.ly/4yjkXtT
Person reclines wearing a cap fitted with multiple electrodes and wires for brain activity monitoring, while a researcher works at a computer in the background. Text reads: “Brain stimulation could reshape how you learn new skills.”
092
Reposted by Dalila
Dr. John Cush @rheumnow.bsky.social · 27/09/2026
Cluster analysis of Spanish RELES #SLE SLE cohort reveals 3 groups. C1 (n 168) was younger, w/ lupus nephritis, low C3, intensive Rx, high infx & damage. C2 (175) w/ cytopenias, serositis, APL & dsDNA(+). C3 (452) mild skin-Jts, less serologic activity & complications buff.ly/Oj3vuij
012
Reposted by Dalila
ACR Journals @acr-journals.bsky.social · 28/09/2026
Cross-sectional study of 451 adults w/ SLE found that 80% used a dietary supplement, and more than half used multiple supplements Almost 1/3 had a potential supplement–medication interaction, highlighting a potential underrecognized patient safety concern in lupus care AC&R doi.org/10.1002/acr....
Individual supplements taken by adults with SLE with prevalence of at least 5%
011
Dalila @dalilatm.bsky.social · 26/09/2026
💻 3+ hours for the latest macOS update 😥 Better include knocking a few years off too #rejuvenating
000
Reposted by Dalila
NEJM.org @nejm.org · 22/09/2026
Our latest video in partnership with @glaucomflecken.bsky.social summarizes the ALLEGORY trial that evaluated the efficacy and safety of obinutuzumab when added to standard therapy in adults with active systemic lupus erythematosus. Read the full study for free: nej.md/DrG49 #rheumatology
0667
Dalila @dalilatm.bsky.social · 24/09/2026
💜 Thank you, Anna, for sharing your lupus story and raising awareness of childhood-onset lupus🦋 @manchestereveningnews.co.uk #lupus #cSLE www.manchestereveningnews.co.uk/news/real-li...
manchestereveningnews.co.uk
'Anna had been complaining of aches for weeks, then she couldn't breathe'
16-year-old Anna Foster was diagnosed with lupus
000
Reposted by Dalila
kahlenberglab.bsky.social @kahlenberglab.bsky.social · 23/09/2026
A paper 4 years n the making is finally out! A single cell map of lupus photosensitive responses. Thanks to our team, our patients, and @lupusresearch.bsky.social for funding this! urldefense.com/v3/__https:/...
urldefense.com
Myeloid infiltration and epidermal dysregulation characterize cutaneous photosensitivity in systemic lupus erythematosus
In photosensitive lupus, dysregulated cutaneous UV responses recruit and activate monocyte-derived dendritic cells that may drive lesion development.
012
Reposted by Dalila
ACR Journals @acr-journals.bsky.social · 23/09/2026
Are some immunosuppressants safer in SLE? In a target trial emulation of 6168 patients, differences in serious infection risk were initially observed across treatments but attenuated after accounting for glucocorticoid exposure Arthritis & Rheumatology doi.org/10.1002/art.... @aliduarte.bsky.social
Comparative Safety of Common Immunosuppressant Therapies in Systemic Lupus Erythematosus: A Target Trial Emulation Study. A graphical abstract
021
Reposted by Dalila
UCL @ucl.ac.uk · 21/09/2026
Today is #WorldAlzheimersDay. At UCL‬ we're tackling the global challenge of #dementia by focusing our world-leading expertise on prevention, care and cure. Explore our research stories to learn more: 🔗 bit.ly/3SwtZE7 #UCLDementia
Purple graphic with a colorful brain scan. Text reads: "#UCLDementia Tackling the global challenge of dementia. World Alzheimer’s Day 2026." UCL logo is in the top right corner.
093
Reposted by Dalila
European Academy of Neurology @ean.org · 21/09/2026
Final chance to register for our migraine during pregnancy webinar! 🧠 Migraine During Pregnancy, Postpartum and Breastfeeding: Understanding the Hormonal Aspect and Implementing Safe Strategies for Acute and Preventive Treatment ⏰ 23.09.26 | 18:00-19:30 CEST 💻 on eanCampus 🔗 buff.ly/xBQ03rQ
021
Reposted by Dalila
Grace Choung, MD 박영이 @gracechoung.bsky.social · 18/09/2026
Early EULAR Target Achievement and Kidney Outcomes in Lupus Nephritis - Kidney International Reports www.kireports.org/article/S246...
kireports.org
Early EULAR Target Achievement and Kidney Outcomes in Lupus Nephritis
The prognostic value of achieving the European League Against Rheumatism (EULAR) 3- and 6-month treatment targets in lupus nephritis (LN) remains uncertain.
033
Reposted by Dalila
The Guardian @theguardian.com · 16/09/2026
Scientists create mice with part-human brains
theguardian.com
Scientists create mice with part-human brains
Researchers hope to shed light on conditions such as schizophrenia, epilepsy, cerebral palsy, intellectual disability and rare forms of dementia Researchers have created mice with half-human brains in an effort to understand and develop new treatments for disorders such as schizophrenia, epilepsy, cerebral palsy, intellectual disability and rare forms of dementia. The scientists transplanted lab-grown human brain cells into animals that were engineered to be born without a cortex or hippocampus. This made space for the human tissue to grow inside the rodents’ skulls. Continue reading...
232311
Reposted by Dalila
Fabien VINCENT @fabozy.bsky.social · 14/09/2026
Beyond conventional biomarkers: can blood metabolomics reveal new clues about #Lupus? Our #Frontiers in #Immunology study identified candidate metabolomic signatures associated with lupus nephritis, remission & glucocorticoid use in #SLE frontiersin.org/journals/imm... @monashuniversity.bsky.social
frontiersin.org
Frontiers | Untargeted serum metabolomics in systemic lupus erythematosus reveals candidate metabolomic signatures associated with clinical phenotypes and glucocorticoid use
Objectives. Despite promising advances in metabolomics for biomarker discovery in systemic lupus erythematosus (SLE), studies examining associations with det...
031
Reposted by Dalila
International Pediatric Nephrology Association @ipna.bsky.social · 14/09/2026
Join us this Wednesday for Juniors Webinar! Navigating the Complexities of Pediatric Lupus Nephritis ⬇️ September 16, 4pm CET Moderator: Patricia Costa-Reis Speakers: Prof Stephen Marks, Prof Scott Wenderfer Registration: us06web.zoom.us/webinar/regi...
021
Reposted by Dalila
Waggoner Lab @labwaggoner.bsky.social · 11/09/2026
Delighted to publish this with my friends in @ajhgnews.bsky.social @cincychildrens.bsky.social IRF7 haplotype amplifies activity with immunological risks and benefits scienceblog.cincinnatichildrens.org/when-antivir... doi.org/10.1016/j.aj... www.science.org/content/arti...
scienceblog.cincinnatichildrens.org
When Antiviral Defense and Autoimmunity Collide: New Insights into Lupus Genetics - Research Horizons
Researchers discovered how a common lupus risk variant may boost antiviral defenses while increasing autoimmunity risk.
033
Reposted by Dalila
The American Journal of Human Genetics @ajhgnews.bsky.social · 11/09/2026
🧬New from Kottyan & co 📄A highly prevalent lupus risk haplotype increases IRF7-dependent induction of IFN-α, enhancing antiviral defense and exacerbating autoimmunity
cell.com
A highly prevalent lupus risk haplotype increases IRF7-dependent induction of IFN-α, enhancing antiviral defense and exacerbating autoimmunity
Virolainen et al. combine human genetics, functional genomics, and mouse models to show that a common lupus-risk IRF7 haplotype enhances IRF7 nuclear localization, DNA binding, and type I interferon production. The haplotype improves antiviral defense but increases autoreactivity, revealing an evolutionary trade-off between host protection and autoimmunity.
012
Reposted by Dalila
University of York Events @uoyevents.bsky.social · 10/09/2026
TODAY at 2pm - Experts discuss the evolving role of External Assessment Groups in shaping evidence, scrutiny, and transparency for NICE decisions. Behind the NICE Curtain www.york.ac.uk/news-and-events/even…
011
Dalila @dalilatm.bsky.social · 09/09/2026
🤩 Wonderful presentation today on autoimmunity & neural dysfunction in Complex Regional Pain Syndrome #CRPS. Lots of mentions of #lupus & how autoimmunity is expressed in CRPS. Data on brain changes seen in CRPS after years of living with persistent pain. 💡Many Qs in autoimmunity needing an answer
011
Dalila @dalilatm.bsky.social · 08/09/2026
While we’re seeing extraordinary advances driven by AI, over the next years it’ll be important to remember the incredible capabilities of humans on their own. Here: Michelangelo’s Moses and Beethoven’s Ninth Symphony (Pics: Wikipedia)
011
Reposted by Dalila
Renal and Urology News @renalurologynews.bsky.social · 03/09/2026
At 12 months, the complete response rate was 36.7% in the supportive care group and 49.6% in patients who received immunosuppressive therapy. www.renalandurologynews.com/news/ri…
renalandurologynews.com
Rituximab Improves CRR, Reduces Steroid Exposure in Lupus Membranous Nephropathy
A real-world study revealed little difference in 12-month renal response rates among immunosuppressive regimens for patients with first-onset PLMN.
021
Reposted by Dalila
Rheumatology Advisor @rheumatologyadv.bsky.social · 04/09/2026
From @jrheumatol.bsky.social: Younger patients with systemic #lupus erythematosus face significantly greater capability and opportunity barriers to treatment adherence compared with older populations. www.rheumatologyadvisor.com/news/lo…
rheumatologyadvisor.com
Adults Younger Than 30 Years With SLE Face More Barriers to Medication Adherence
Medication nonadherence in systemic lupus erythematosus is highest among younger adults facing access and scheduling barriers.
021
Dalila @dalilatm.bsky.social · 05/09/2026
Watched ☑️ Beautifully structured, with the key concepts well defined and linked together in a topic that’s far from black & white 👍👏🏻 #lupus @lupusacademy.bsky.social
120
Dalila @dalilatm.bsky.social · 05/09/2026
🦋 A new day, a new (and last) round of lupus sessions. More lupus food for thought 💭 Starting with ‘Signatures in SLE’, Ioannis Parodis #lupus @lupusacademy.bsky.social
000
Dalila @dalilatm.bsky.social · 04/09/2026
It isn't only about ‘thinking’ the same, but also ‘seeing’ the same, as everyone is using the same AI-generated graphic style for posters and leaflets @nature.com #AI #graphicDesign "Bland new world: is AI making us all think the same?" www.nature.com/articles/d41...
nature.com
Bland new world: is AI making us all think the same?
Researchers worry that generative AI is homogenizing culture and cognition.
020
Reposted by Dalila
ACR Journals @acr-journals.bsky.social · 01/09/2026
September A&R Clinical Connections (1 of 2): Multi-Omic Profiling Reveals Immune Cell Priming Signature in Lupus Key Points: • Proteins released from inflamed tissues could be detected in the blood of patients with lupus. continues
Multi-Omic Profiling Reveals Immune Cell Priming Signature in Lupus
111
Dalila @dalilatm.bsky.social · 04/09/2026
Interesting short talk on the neurological effects of #menopause, & perimenopause as a neurological transition phase involving changes in the brain. Sth I’ve often wondered about when listening to women with #lupus talk about their experiences of brain fog #TheFemHealthProject @springernature.com
110
Reposted by Dalila
Science Seminars @scienceseminars.org · 03/09/2026
Science Seminar on 10 September at 2pm London / 9am EST with Professor Alex K. Shalek (MIT) on Identifying & Counteracting the Impact of Environmental Stress on Tissue Function. Please register at shorturl.at/RLBNc @shaleklab.bsky.social @broadinstitute.org
043
Reposted by Dalila
The Journal of Rheumatology @jrheumatol.bsky.social · 02/09/2026
Editorial PROducing More Evidence to Reduce Glucocorticoids in Systemic Lupus Erythematosus: Putting Patient-Reported Outcomes in the Picture 📖 doi.org/10.3899/jrhe... @monashuniversity.bsky.social #Glucocorticoids #Lupus
011
Reposted by Dalila
The Journal of Rheumatology @jrheumatol.bsky.social · 02/09/2026
Research Article Association of Daily Glucocorticoid Dose With Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Data From the Almenara Lupus Cohort 📖 www.jrheum.org/cgi/content/... #Fatigue #Glucocorticoids #Lupus
011
Dalila @dalilatm.bsky.social · 03/09/2026
🤔 Apart from sharing the name (lupus = wolf), which comes from the disease’s early presentation, I’m not a huge fan of delving into the biology & characteristics of wolves 🐺 & drawing comparisons when talking about #lupus as a disease 🙅‍♀️
000
Dalila @dalilatm.bsky.social · 31/08/2026
Well done to all the parents for making it through the 6 weeks of summer holidays 👍 May you enjoy your first scream-free coffee in peace… also known as the first day back at school ☕
000
Reposted by Dalila
ACR Journals @acr-journals.bsky.social · 28/08/2026
New US data from 5 CDC lupus registries show striking age differences in SLE incidence: rates peak at ages 30–39 in women, but 60–69 in men. Black women ages 20–39 had the highest incidence. Important insights into who develops lupus and when Arthritis & Rheumatology doi.org/10.1002/art....
Age‐specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta‐Analysis of Data from the Centers for Disease Control and Prevention Lupus Registries. Graphical abstract created using BioRender
011
Reposted by Dalila
Biblioteca Virtual del SSPA @bvsspa.bsky.social · 28/08/2026
🫀 “Subclinical Atherosclerosis Risk Can Be Predicted in Female Patients With Systemic Lupus Erythematosus Using Metabolomic Signatures: An Observational Study” @cabimer.bsky.social 👉 Disponible en #RISalud hdl.handle.net/10668/31084 #BVSSPA #RISalud #Aterosclerosis #Lupus
011
Reposted by Dalila
UK Kidney Association @ukkidney.org · 29/08/2026
⏰Last chance to share your insights The Glomerulonephritis SIG medicines workstream invites secondary care HCPs to complete a 5-min survey on the use of obinutuzumab for lupus nephritis & other kidney conditions. ⏱️ Closes tomorrow (30 Aug) 📝 Complete now: ow.ly/VIrJ50Zv4qj #KidneyCare
011
Reposted by Dalila
Science Magazine @science.org · 24/08/2026
By analyzing more than 800,000 single-cell profiles in tissues and blood, researchers assemble a massive biomolecular compendium of lupus nephritis that maps out its impact on cell populations and could inform future therapeutics. #ScienceTranslationalMedicine scim.ag/4qz1G4C
scim.ag
A population-scale transcriptional atlas of blood and tissue in lupus nephritis
A single-cell transcriptomic atlas identified stromal and immune populations in renal tissue associated with lupus nephritis disease activity.
0182
Reposted by Dalila
NKF Nephrology Professionals @nkf-professionals.bsky.social · 25/08/2026
What do the 2024 KDIGO recommendations mean for lupus nephritis care? Join host Osama El Shamy, MD, with Gabriel Contreras, MD, MPH, and Sayna Norouzi, MD, for practical insights in this episode. bit.ly/3DamjQ9 (Episode 062) #LupusNephritis #KDIGO
bit.ly
https://bit.ly/3DamjQ9
012
Reposted by Dalila
Chris Wincup @chriswincup.bsky.social · 26/08/2026
🧬 Delighted to share our new review in @RheumJnl on B cell targeting in #lupus From monoclonals to T cell engagers & CAR-T A pleasure working with brilliant co-authors Mariele Gatto, Marc Scherlinger, Georg Schett & Melanie Hagen💡 Open access link 🔗 academic.oup.com/rheumatology...
021
Reposted by Dalila
University of Oxford @ox.ac.uk · 25/08/2026
NEW: An Oxford brain imaging and stimulation study has identified the brain mechanisms that help us work out whether the consequences we experience are caused by our own actions or by circumstances beyond our control. Read more ⬇️ bit.ly/4xUULVG
A digital illustration of a human profile with a colorful, illuminated brain, set against a blue, radiant background. Text below reads: "Brain imaging study reveals how we decide whether we are in control".
0123
Dalila @dalilatm.bsky.social · 25/08/2026
Interesting article 👍 Indeed, it’s clear how rapidly the #lupus landscape has been changing in recent years. Agree that ‘living’ guidelines could help capture these developments, together with a single ‘global evidence base’ rather than each society conducting its own evidence review (1/2)...
100
Reposted by Dalila
JAACAP Journals @jaacapjournals.bsky.social · 21/08/2026
Depression in youth with SLE contributes to poorer adherence, increased disease activity, and diminished quality of life, yet it is often unrecognized in routine rheumatologic care. 2/5
111
Reposted by Dalila
JAACAP Journals @jaacapjournals.bsky.social · 21/08/2026
This Clinical Perspectives manuscript examines depression as a frequently overlooked but clinically consequential comorbidity in pediatric systemic lupus erythematosus (SLE). twp.ai/E5ENWA 1/5
111
Reposted by Dalila
Royal Free Charity @royalfreecharity.org · 17/08/2026
New paper alert 🔬 We helped fund George Robinson's (UCL) study in Annals of the Rheumatic Diseases. It finds LAMP3 as a biomarker for interferon activity in childhood #lupus, guiding personalised treatment. 📄 Paper: ard.eular.org/article/S000... 🧪 Lupus explained: youtu.be/bXHFWIwRWE0
ard.eular.org
Type I interferon endotypes drive divergent clinical trajectories in childhood-onset SLE uncovered through a novel systems immunology approach
Childhood-onset systemic lupus erythematosus (cSLE) is a severe autoimmune disease with significant morbidity and enhanced type I interferon (IFN-I) signalling, potentially contributing to its aggress...
012
Reposted by Dalila
Dr. John Cush @rheumnow.bsky.social · 20/08/2026
Childhood vs Adult onset SLE? Retro Australian Lupus Registry study of 519 SLE pts (68/13% w/ cSLE) found childhood onset had signif more damage (SDI≥1 53 vs 40%; renal Dz 62 vs 37%), more Dz activity, less LLDAS-50 (36% vs 51%) pmc.ncbi.nlm.nih.gov/articles/PMC...
pmc.ncbi.nlm.nih.gov
High disease activity persists in adults with childhood-onset lupus
Childhood-onset SLE (cSLE) is often described as more severe than adult-onset disease (aSLE) based largely on cross-sectional studies. We examined differences in disease characteristics, medication…
011
Dalila @dalilatm.bsky.social · 16/08/2026
So much heat & no rain at all for so long that I’m actually craving a heavy snowy day ⛄️😵‍💫
000
Reposted by Dalila
Yale Nephrology @yalenephrology.bsky.social · 13/08/2026
How do B cells survive the hypertonic kidney in lupus nephritis? At Medical Grand Rounds, Dr. Irene Chernova took us from the γ subunit of the Na-K-ATPase to extracellular ATP signaling via P2RX4 and P2RX7. Genuinely surprising axis & terrific discussion. Excited for what's next!
0105
Reposted by Dalila
ISNkidneycare @theisn.org · 11/08/2026
𝗜𝗦𝗡 𝗩𝗜𝗗𝗘𝗢 𝗔𝗕𝗦𝗧𝗥𝗔𝗖𝗧 𝗦𝗘𝗥𝗜𝗘𝗦: Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis. 2026 from @kidneyint.bsky.social bit.ly/4odxoD5 #VideoAbstract by @raphapalma.bsky.social & @drsumanbehera.bsky.social
032
Reposted by Dalila
Lupus Foundation of America @lupus.org · 11/08/2026
For kids with #lupus, managing your health at school starts with making smart decisions and knowing how you feel. 📚 Swipe through our School Survival Guide to learn how to advocate and make school as productive and fun as possible. Read the guide: buff.ly/BXvnuo9
151
Reposted by Dalila
ACR Journals @acr-journals.bsky.social · 06/08/2026
Prospective study of 248 patients with SLE showed patients with both very low HCQ levels (<200 ng/mL) and poor long-term intake (adherence <80% over 6-12 months) had higher atherosclerotic cardiovascular disease risk Arthritis Care & Research doi.org/10.1002/acr....
Optimizing Hydroxychloroquine Blood Levels and Long-Term Hydroxychloroquine Intake Could Lower ASCVD Risk and Prevent Polypharmacy in Systemic Lupus Erythematosus. Graphical abstract created using BioRender
011
Reposted by Dalila
Yale Nephrology @yalenephrology.bsky.social · 07/08/2026
Renal Rounds this morning: 2nd year fellow Dr. Erica Marnet on “Lupus Nephritis: Treatment Paradigm.” Dysregulated B cells, sustained interferon signaling & how the mechanisms map onto what we actually reach for in clinic.
042
Reposted by Dalila
JCI insight @insight.jci.org · 04/08/2026
Presenting the most comprehensive proteomic map of systemic lupus erythematosus to date! doi.org/10.1172/jci.... Leung et al. @imperialcollegeldn.bsky.social report potential therapeutic targets, biomarkers & autoantibody-linked proteomic signatures in SLE, providing a basis for precision medicine
121